Genetic, cellular and molecular mechanisms of pulmonary arterial hypertension

被引:10
作者
Alan, Bahadir [1 ]
Nalbantgil, Sanem [1 ]
机构
[1] Ege Univ Tip Fak, Kardiyoloji Anabilim Dali, Izmir, Turkey
关键词
Pulmonary arterial hypertension; bone morphogenic protein receptor type 2; activin-like kinase type 1; endoglin; ENDOTHELIAL GROWTH-FACTOR; BMPR2; MUTATIONS; EXPRESSION; ELASTASE; RECEPTOR; FENFLURAMINE; PREVENTS; RATS; MICE;
D O I
10.5152/akd.2010.114
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Pulmonary arterial hypertension (PAH) is an uncommon disorder that may be hereditable, idiopathic or associated with conditions like drug exposure, connective tissue disease, HIV infection or congenital heart disease. Familial disease are usually due to mutations in the bone morphogenic protein receptor type 2 (BMPR2), activin-like kinase-type 1 (ALK1) and endoglin (ENG). Functional and structural changes in the pulmonary vasculature lead to increased pulmonary vascular resistance. Vascular remodeling involves endothelial dysfunction, activation of fibroblasts and smooth muscle cells and recruitment of circulating progenitor cells. Vasoconstriction has also been shown to affect the remodeling process. Genetics, cellular and molecular basis of PAH are discussed in the paper. (Anadolu Kardiyol Derg 2010; 10: Suppl 1; 9-13)
引用
收藏
页码:9 / 13
页数:5
相关论文
共 38 条
[1]
Characterization of the BMPR2 5′-untranslated region and a novel mutation in pulmonary hypertension [J].
Aldred, Micheala A. ;
Machado, Rajiv D. ;
James, Victoria ;
Morrell, Nicholas W. ;
Trembath, Richard C. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2007, 176 (08) :819-824
[2]
Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor [J].
Atkinson, C ;
Stewart, S ;
Upton, PD ;
Machado, R ;
Thomson, JR ;
Trembath, RC ;
Morrell, NW .
CIRCULATION, 2002, 105 (14) :1672-1678
[3]
Plasma markers of endothelial dysfunction in pulmonary hypertension [J].
Cella, G ;
Bellotto, F ;
Tona, F ;
Sbarai, A ;
Mazzaro, G ;
Motta, G ;
Fareed, J .
CHEST, 2001, 120 (04) :1226-1230
[4]
Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension [J].
Chaouat, A ;
Coulet, F ;
Favre, C ;
Simonneau, G ;
Weitzenblum, E ;
Soubrier, F ;
Humbert, M .
THORAX, 2004, 59 (05) :446-448
[5]
AN IMBALANCE BETWEEN THE EXCRETION OF THROMBOXANE AND PROSTACYCLIN METABOLITES IN PULMONARY-HYPERTENSION [J].
CHRISTMAN, BW ;
MCPHERSON, CD ;
NEWMAN, JH ;
KING, GA ;
BERNARD, GR ;
GROVES, BM ;
LOYD, JE .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (02) :70-75
[6]
Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor [J].
Cowan, KN ;
Heilbut, A ;
Humpl, T ;
Lam, C ;
Ito, S ;
Rabinovitch, M .
NATURE MEDICINE, 2000, 6 (06) :698-702
[7]
Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease [J].
Cowan, KN ;
Jones, PL ;
Rabinovitch, M .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (01) :21-34
[8]
DRESDALE DT, 1954, B NEW YORK ACAD MED, V30, P195
[9]
Du Lingling, 2003, New England Journal of Medicine, V348, P500, DOI 10.1056/NEJMoa021650
[10]
Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension [J].
Elliott, C. Gregory ;
Glissmeyer, Eric W. ;
Havlena, Gregory T. ;
Carlquist, John ;
McKinney, Jason T. ;
Rich, Stuart ;
McGoon, Michael D. ;
Scholand, Mary Beth ;
Kim, Miryoung ;
Jensen, Robert L. ;
Schmidt, Jon W. ;
Ward, Kenneth .
CIRCULATION, 2006, 113 (21) :2509-2515